Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELAGOLIX vs PREGNYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.
Human chorionic gonadotropin (h CG) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads, stimulating testosterone production in males and ovulation in females.
Management of moderate to severe pain associated with endometriosis
FDA: Treatment of prepubertal cryptorchidism,FDA: Induction of ovulation and pregnancy in anovulatory infertile women,Off-label: Hypogonadotropic hypogonadism in males,Off-label: Assisted reproductive technology (ART) protocols
200 mg orally twice daily
Intramuscular injection: 5,000-10,000 IU once weekly for 4-9 weeks for ovulation induction; 1,000-2,000 IU three times weekly for spermatogenesis.
Terminal elimination half-life is approximately 4–6 hours. Clinical context: Steady state achieved within 5 days; tid dosing maintains therapeutic concentrations.
Terminal elimination half-life: 23–24 hours; clinically, supports daily or every-other-day dosing; peak effect may lag due to prolonged absorption
Primarily metabolized by CYP3A4; minor contribution from CYP2D6 and CYP2C8.
Primarily renal metabolism and excretion; limited hepatic metabolism.
Renal (approximately 70% as unchanged drug and metabolites), fecal (approximately 30%)
Renal: 10-20% as unchanged drug; hepatic metabolism to inactive metabolites; fecal excretion negligible (<5%)
Approximately 99% bound to albumin and alpha-1-acid glycoprotein
~80% bound primarily to albumin; minor binding to sex hormone-binding globulin (SHBG)
Vd/F is approximately 40–60 L (0.5–0.8 L/kg). Clinical meaning: Extensive tissue distribution, consistent with a large volume of distribution.
0.5–0.7 L/kg; moderately distributed into extracellular fluid; penetrates gonadal tissues
Oral: Approximately 30% (low due to first-pass metabolism); food increases exposure by approximately 30%.
Intramuscular: ~100%; Subcutaneous: comparable (~95-100%); Oral: <5% (not used)
e GFR 30-89 m L/min: no adjustment. e GFR 15-29 m L/min: 100 mg twice daily. e GFR <15 m L/min: not recommended.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Child-Pugh A: no adjustment. Child-Pugh B: 100 mg twice daily. Child-Pugh C: not recommended.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment.
Not established; safety and efficacy in pediatric patients have not been studied.
Not indicated for prepubertal children; for delayed puberty in males: 1,000-2,000 IU intramuscularly 2-3 times weekly for 3-6 months.
No specific dose adjustment required; clinical studies included limited patients ≥65 years, but no differences in safety or efficacy observed.
No specific recommendations; use lowest effective dose due to potential increased sensitivity and comorbidities.
None
No FDA black box warning.
Hepatic transaminase elevations: monitor liver function before and during treatment; discontinue if elevation >3x ULN or if signs of liver injury occur.,Bone density loss: monitor bone mineral density with long-term use; consider additional calcium/vitamin D.,Mood changes: increased risk of depression, suicidal ideation; monitor for new or worsening symptoms.,Altered menstrual bleeding; exclude pregnancy before starting.,Risk of osteoporosis with prolonged use.
Ovarian hyperstimulation syndrome (OHSS) in women,Arterial thromboembolism,Precocious puberty in males,Fluid retention,Ovarian enlargement or cyst rupture
Known hypersensitivity to elagolix or any excipients,Concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine, gemfibrozil),Pregnancy, or women of reproductive potential not using effective contraception,Existing osteoporosis or severe bone loss,History of suicidal ideation or behavior
Hypersensitivity to h CG or any component,Premature epiphyseal closure in males,Androgen-dependent neoplasia (e.g., prostate cancer),Undiagnosed uterine bleeding,Ovarian cyst or enlargement due to polycystic ovarian syndrome (PCOS),Active thromboembolic disorders
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase elagolix levels. No other food restrictions.
No known clinically significant food interactions. Maintain usual diet unless advised otherwise by physician.
First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for harm. Elagolix is contraindicated in pregnancy.
Pregny (h CG) is not indicated for use during pregnancy. h CG is used to induce ovulation and is not continued after conception. In animal studies, high doses have shown fetal abnormalities, but human data are insufficient. First trimester: No direct fetal risk from therapeutic use as it is discontinued before implantation. Second/Third trimester: Not used. Overall, classified as FDA Pregnancy Category X for ovulation induction (contraindicated in pregnancy) but no teratogenic risk if discontinued before conception.
Elagolix is excreted in animal milk; no human data. M/P ratio unknown. Not recommended during breastfeeding.
Human chorionic gonadotropin (h CG) is normally present in breast milk in low concentrations. Exogenous h CG is likely excreted into breast milk, but the M/P ratio is not established. Due to lack of data and potential for adverse effects in the infant (e.g., hormonal disruption), breastfeeding is not recommended during therapy. The manufacturer advises discontinuing breastfeeding or avoiding the drug.
No dose adjustments studied; contraindicated in pregnancy. No data on PK changes requiring dose modification.
Pregny is contraindicated in pregnancy. No dose adjustment is applicable as it is discontinued prior to conception. There are no pharmacokinetic data for pregnancy, but the drug is not used during gestation.
Elagolix is an oral Gn RH antagonist for endometriosis-associated pain. Monitor bone mineral density (BMD) with dual-energy X-ray absorptiometry (DXA) if using >12 months or in patients with osteoporosis risk. Avoid use with strong CYP3A inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole). May reduce efficacy of hormonal contraceptives. Assess pregnancy status before starting due to teratogenicity.
Pregnyl (h CG) is used to trigger final follicular maturation and ovulation in assisted reproduction. Monitor for ovarian hyperstimulation syndrome (OHSS); consider withholding h CG if estradiol >4000 pg/m L or >20 follicles per ovary. Administer exactly 36 hours before oocyte retrieval. Intramuscular injection into gluteal muscle; rotate sites if repeated doses.
Take elagolix at the same time daily with or without food.,Avoid grapefruit or grapefruit juice during treatment.,Use non-hormonal contraception (e.g., condoms) because elagolix may reduce hormonal contraceptive effectiveness.,Report severe headaches, vision changes, or heavy bleeding promptly.,Do not take elagolix if pregnant or planning to become pregnant; use effective birth control.
Use Pregnyl exactly as prescribed to trigger ovulation; timing is critical for egg retrieval.,Report severe pelvic pain, bloating, nausea, or rapid weight gain (possible OHSS) immediately.,Avoid pregnancy tests during treatment as h CG may cause false positive.,May cause injection site pain or swelling; apply warm compress if needed.,Do not discontinue without consulting your fertility specialist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELAGOLIX vs PREGNYL, answered by our medical review team.
ELAGOLIX is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.. PREGNYL is a Gonadotropin Hormone that works by Human chorionic gonadotropin (h CG) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads, stimulating testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELAGOLIX and PREGNYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELAGOLIX is: 200 mg orally twice daily. The standard adult dose of PREGNYL is: Intramuscular injection: 5,000-10,000 IU once weekly for 4-9 weeks for ovulation induction; 1,000-2,000 IU three times weekly for spermatogenesis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELAGOLIX and PREGNYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELAGOLIX is classified as Category C. First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for. PREGNYL is classified as Category C. Pregny (hCG) is not indicated for use during pregnancy. hCG is used to induce ovulation and is not continued after conception. In animal studies, high doses have shown fetal abnorm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.